US FDA Approves Rybrevant (amivantamab) + Lazcluze (lazertinib) for non-small cell lung cancer скачать в хорошем качестве

US FDA Approves Rybrevant (amivantamab) + Lazcluze (lazertinib) for non-small cell lung cancer

n this video, we discuss the recent FDA approval of Johnson & Johnson’s Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) as a first-line, chemotherapy-free treatment for advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations. This combination therapy has shown superior efficacy compared to Tagrisso in the Phase III MARIPOSA trial, reducing the risk of disease progression or death by 30% and extending progression-free survival by an additional seven months. Learn more about the indications, mechanism of action, dosage, administration, potential side effects, and key warnings associated with this groundbreaking treatment. Don’t forget to like, subscribe, and stay informed about the latest medical advancements! Warning: The information provided in this video is for educational and informational purposes only and is not intended as medical advice. It is not a substitute for professional medical diagnosis, treatment, or advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have learned from this video or any linked materials.